People's Fortune Pharmaceuticals: Lis's Transdermal Patch has obtained a drug registration certificate.

Renfu Pharmaceuticals announced that its holding subsidiary Yichang Renfu recently received the "Drug Registration Certificate" for Rivastigmine Transdermal Patch issued by the National Medical Products Administration. Rivastigmine Transdermal Patch is approved for the indication of treating mild to moderate symptoms of Alzheimer's disease. Yichang Renfu submitted the application for market approval of Rivastigmine Transdermal Patch to the National Medical Products Administration in March 2023 and it has been accepted. As of now, the project has accumulated research and development investment of approximately 19 million RMB.